Biochemical Characteristics, Treatment, and Outcomes of Thyrotoxicosis in Amiodarone-Treated Individuals with Prior Hypothyroidism

BACKGROUND: Evidence regarding the transition from hypothyroidism to thyrotoxicosis in amiodarone-treated patients remains scarce. We compared clinical characteristics, treatments, and outcomes of amiodarone-exposed individuals developing thyrotoxicosis following hypothyroidism (post-hypo-T) versus those without prior thyroid disease (T-controls). METHODS: This retrospective cohort study utilized electronic health records from a large health maintenance organization (HMO). We included adults from the cardiovascular disease registry with new-onset thyrotoxicosis diagnosed between January 1, 2010, and December 31, 2022, who received amiodarone within the year preceding diagnosis. Follow-up ended on August 31, 2025. Cox regression models adjusted for age and sex were used to analyze outcomes. RESULTS: Of 558 individuals, 91 (16%) had prior hypothyroidism and 467 were controls. Post-hypo-T patients were older (70.4±10.1 vs. 67.4±11.0 years; p = 0.02) and had a higher proportion of males (44.0% vs. 25.3%; p < 0.001). Median amiodarone exposure prior to diagnosis was 2.7 versus 2.8 years, respectively (p = 0.01). At diagnosis, post-hypo-T individuals had lower median free thyroxine (fT4) levels (27.0 vs. 31.3 pmol/L; p < 0.001) and free triiodothyronine (fT3) levels (6.4 vs. 7.5 pmol/L; p < 0.001).Over a 7.8-year median follow-up, antithyroid medications were used less frequently in post-hypo-T individuals (37.4% vs. 54.0%; p = 0.004). Glucocorticoid use was numerically lower in post-hypo-T individuals (26.4% vs. 38.5%; p = 0.06). Post-hypo-T individuals had a higher incidence of hypothyroidism requiring levothyroxine (64.8% vs. 17.8%; p < 0.001). CONCLUSIONS: Among amiodarone-exposed individuals who develop thyrotoxicosis, those with prior hypothyroidism have a milder biochemical presentation, less frequent use of antithyroid drugs or glucocorticoids, and a higher likelihood of recurrent hypothyroidism requiring levothyroxine.

Authors

Institutions

Publication Details

Journal
Endocrine Connections
Published
2026-11-12
DOI
https://doi.org/10.1530/ec-26-0539
Primary Topic
Thyroid Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Biochemical Characteristics, Treatment, and Outcomes of Thyrotoxicosis in Amiodarone-Treated Individuals with Prior Hypothyroidism

Afif Nakhleh, Sagit Zolotov, Ori Liran, Shirley Shapiro Ben David et al.
Endocrine Connections
Thyroid Disorders and Treatments
article

Biochemical Characteristics, Treatment, and Outcomes of Thyrotoxicosis in Amiodarone-Treated Individuals with Prior Hypothyroidism

Afif Nakhleh, Sagit Zolotov, Ori Liran, Shirley Shapiro Ben David, Daniella Rahamim‐Cohen, Limor Adler
article en

Abstract

BACKGROUND: Evidence regarding the transition from hypothyroidism to thyrotoxicosis in amiodarone-treated patients remains scarce. We compared clinical characteristics, treatments, and outcomes of amiodarone-exposed individuals developing thyrotoxicosis following hypothyroidism (post-hypo-T) versus those without prior thyroid disease (T-controls). METHODS: This retrospective cohort study utilized electronic health records from a large health maintenance organization (HMO). We included adults from the cardiovascular disease registry with new-onset thyrotoxicosis diagnosed between January 1, 2010, and December 31, 2022, who received amiodarone within the year preceding diagnosis. Follow-up ended on August 31, 2025. Cox regression models adjusted for age and sex were used to analyze outcomes. RESULTS: Of 558 individuals, 91 (16%) had prior hypothyroidism and 467 were controls. Post-hypo-T patients were older (70.4±10.1 vs. 67.4±11.0 years; p = 0.02) and had a higher proportion of males (44.0% vs. 25.3%; p < 0.001). Median amiodarone exposure prior to diagnosis was 2.7 versus 2.8 years, respectively (p = 0.01). At diagnosis, post-hypo-T individuals had lower median free thyroxine (fT4) levels (27.0 vs. 31.3 pmol/L; p < 0.001) and free triiodothyronine (fT3) levels (6.4 vs. 7.5 pmol/L; p < 0.001).Over a 7.8-year median follow-up, antithyroid medications were used less frequently in post-hypo-T individuals (37.4% vs. 54.0%; p = 0.004). Glucocorticoid use was numerically lower in post-hypo-T individuals (26.4% vs. 38.5%; p = 0.06). Post-hypo-T individuals had a higher incidence of hypothyroidism requiring levothyroxine (64.8% vs. 17.8%; p < 0.001). CONCLUSIONS: Among amiodarone-exposed individuals who develop thyrotoxicosis, those with prior hypothyroidism have a milder biochemical presentation, less frequent use of antithyroid drugs or glucocorticoids, and a higher likelihood of recurrent hypothyroidism requiring levothyroxine.

Endocrine Connections
Bar-Ilan University (IL), Tel Aviv University (IL), Rambam Health Care Campus (IL), Maccabi Healthcare Services (IL)
Good health and well-being
Thyroid Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon